Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies

摘要

The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed does of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designating a personalized therapy.

主权项

1. A method of treating an adult patient having a systemic lupus erythematosus (SLE) comprising intravenously administering monthly to the adult patient a fixed dose comprising 300 mg or 1000 mg of an antibody or antigen-binding fragment thereof comprising the amino acid sequences of SEQ ID NO: 1 and SEQ ID No: 2.